Toku welcomes Dr Robert Weinreb to Board of Directors
May 03 2024 - 11:00AM
Business Wire
Toku is pleased to announce the appointment of Robert N. Weinreb
MD to its Board of Directors. Renowned globally for his
contributions to ophthalmology, Dr. Weinreb's appointment
underscores Toku's commitment to excellence and innovation in eye
care. “We are thrilled to welcome Dr. Weinreb to our Board! Working
with him, we will accelerate our leadership in healthcare through
the eye,” according to Ehsan Vaghefi, President and CEO.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240503241739/en/
Dr Robert Weinreb has joined Toku Inc.'s
board of directors (Photo: Business Wire)
Dr. Weinreb's distinguished career encompasses groundbreaking
research and clinical practice. As the Chair and Distinguished
Professor of Ophthalmology at the University of California, San
Diego, and Director of the Shiley Eye Institute and the Hamilton
Glaucoma Center. This week it was announced that Dr Weinreb joined
the Ophthalmologist Power List Hall of Fame. He brings unparalleled
expertise to the Toku board. “I am excited to join Toku's Board of
Directors. The company's groundbreaking work is certain to have a
meaningful impact on the lives of patients throughout the world,”
comments Dr. Weinreb.
About Toku, Inc.
Toku, Inc. is a cutting-edge technology company that specializes
in developing non-invasive, AI-powered diagnostic and screening
tools using retinal imaging to measure cardiovascular and other
health risk factors. The company’s first commercialized product,
BioAge, analyzes biometric markers visible in the retinal image to
accurately measure an individual’s biological age. The test can
provide a detailed report on an individual’s overall health. The
Company is also developing the CLAiR platform, an AI-powered
technology to assess cardiovascular risk by means of retinal
photographs of the back of the eye. The CLAiR platform has received
Breakthrough Device designation from the FDA in November 2023 and
CE & UKCA Marks in 2024. MyKidneyAI is the latest in Toku’s
suite of products. Toku is committed to making its technology
widely accessible through its major partnerships across the world.
The company’s technology is built on the latest research in AI, and
its team of experts includes leading scientists and medical
professionals.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240503241739/en/
Media Francesca Logan Francesca.logan@tokueyes.com